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 10 
Abstract 11 
Adverse tissue responses to prostheses wear particles and released ions are important 12 
contributors to hip implant failure. In implant-related adverse reactions T-lymphocytes play a 13 
prominent role in sustaining the chronic inflammatory response. To further understand the 14 
involvement of lymphocytes in metal-on-metal (MoM) implant failure, primary human 15 
lymphocytes were isolated and treated with CoCr wear debris and Co ions, individually, and 16 
in combination, for 24, 48, and 120h. There was a significant increase in cell number where 17 
debris was present, as measured by the Neutral Red assay. Interleukin 6 (IL-6), LQWHUIHURQȖ18 
(,)1Ȗ), and WXPRXUQHFURVLV IDFWRUĮTNFĮVHFUHWLRQ OHYHOVVLJQLILFDQWO\GHFUHDVHG LQ WKH19 
presence of metal particles, as measured by ELISA. Interleukin 2 (IL-2) secretion levels were 20 
significantly decreased by both debris and Co ions. Flow cytometry analysis showed that the 21 
metal nanoparticles induced a significant increase in apoptosis after 48h exposure. This 22 
investigation showed that prolonged exposure (120h) to metal debris induces lymphocyte 23 
proliferation, suggesting that activation of resting lymphocytes may have occurred. Although 24 
cytokine production was affected mainly by metal debris, cobalt toxicity may also modulate 25 
IL-2 secretion, and even Co ion concentrations below the MHRA guideline levels (7ppb) may 26 
contribute to the impairment of immune regulation in vivo in patients with MoM implants. 27 
 28 
Short abstract 29 
In implant-related adverse reactions T-lymphocytes play a prominent role in sustaining the 30 
chronic inflammatory response. Primary human lymphocytes were isolated and treated with 31 
CoCr wear debris and Co ions, individually, and in combination, for 24, 48, and 120h. 32 
Prolonged exposure to metal debris induced lymphocyte proliferation, suggesting that 33 
activation of resting lymphocytes may have occurred. Furthermore, cobalt toxicity may 34 
modulate IL-2 secretion, which may contribute to the impairment of immune regulation in 35 
vivo in patients with MoM implants. 36 
 37 
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 44 
Introduction  45 
Modern day metal-on-metal (MoM) total hip resurfacings were introduced in the 1990s 46 
(Quesada et al., 2008). They represented approximately 10% of all hip arthroplasties in 47 
developed countries between 1990 and 2010 (Corten and MacDonald, 2010; Jiang et al., 48 
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2011). MoM hip resurfacing bearings are made from high-carbon CoCr alloy (Amstutz and 49 
Le Duff, 2006; Mahendra et al., 2009) . 50 
 51 
The most common cause of failure of total hip arthroplasty is aseptic loosening of the implant 52 
due predominantly to adverse tissue responses to prostheses wear particles (Luo et al., 2005). 53 
Host response to a prosthesis or prosthetic debris results in the formation of a fibrous 54 
synovial-like membrane surrounding the prosthesis (Wang et al., 1996). It is believed that 55 
mononuclear phagocytic cells in the pseudomembrane surrounding the implant phagocytose 56 
wear particles and become activated. This activation results in the release of pro-57 
inflammatory cytokines, such as IL-6 and TNF-Į DQG LQIODPPDWRU\ PHGLDWRUV VXFK DV58 
PGE2, which stimulate osteoclastic bone resorption (Ingham et al., 2000). Lymphocytes are 59 
known to be important regulators of macrophage function (Arora et al., 2003). T cells are 60 
recognised as modulators of immune response pathways as a result of stimulation of either 61 
the Th1 or Th2 pathway, which involves cell types and cytokines that may influence 62 
loosening of total hip replacements (Cachinho et al., 2013). The Th1-cell response is crucial 63 
to the activation of macrophages and cytotoxic T-lymphocytes and is involved in the cell-64 
mediated immune response. On the other hand, the Th2-cell response is the most effective 65 
activator of B-lymphocytes and is associated with humoral immunity (Cachinho et al., 2013).  66 
 67 
 T lymphocytes also play a prominent role in cell mediated type IV hypersensitivity reactions 68 
sustaining the chronic inflammatory response. Cell-mediated type-IV hypersensitivity 69 
reactions are characterised in vivo by vasculitis with perivascular and intramural lymphocytic 70 
infiltration of the postcapillary venules, swelling of the vascular endothelium, recurrent 71 
localised bleeding, and necrosis which has been reported following MoM hip replacements 72 
(Willert et al., 2005). Lymphocyte infiltrates have also been reported in soft-tissue masses, 73 
described as pseudo-tumours, following MoM resurfacing arthroplasty (Boardman et al., 74 
2006; Pandit et al., 2008).  75 
 76 
Metals modulate the activities of immunocompetent cells by a variety of mechanisms. The 77 
outcome of this modulation depends on the particular metal, its concentration and biological 78 
availability (Lawrence and McCabe, 2002). A variety of soluble metals, including Co2+ and 79 
Cr3+, at a range of concentrations between 0.05 and 5mM were found to induce Jurkat T-80 
lymphocyte DNA damage, apoptosis, and/or direct necrosis in a metal-, and concentration-81 
dependent manner (Caicedo et al., 2008).  82 
 83 
Co corrodes faster than Cr under physiological conditions (Xia et al., 2011) and, contrary to 84 
Cr, Co ions tend to remain mobile, which is reflected in the higher levels measured in blood, 85 
allowing them to reach remote organs (Afolaranmi et al., 2012). Data from the seventh 86 
annual report of the National Joint Registry for England and Wales showed high failure rates 87 
for MoM hip prostheses, which led to the market recall of the DePuy ASRTM, both the 88 
Resurfacing and XL Systems in August 2010 (DePuy International Ltd, Leeds, UK) 89 
(MDA/2010/069). Following this, the Medicines and Healthcare products Regulatory Agency 90 
(MHRA) safety alert in September 2010 drew attention to the long term biological safety of 91 
all types of MoM hip implants. The MHRA have suggested that combined whole blood Co 92 
and Cr levels of greater than 7ppb (7µg/l or 0.1µM) are associated with significant soft-tissue 93 
reactions and failed MoM hips (MDA/2010/069). However, there is still considerable debate 94 
about the existence of a safe threshold. 95 
 96 
In the present study, the effects of CoCr alloy wear debris and Co ions on primary human 97 
lymphocytes were explored in terms of viability, proliferation, cytokine production, and 98 
3 
 
apoptosis. Release of Co and Cr ions from the CoCr debris was measured at physiological pH 99 
of 7.4, and at the pH estimated to exist in inflammatory conditions (Mansson et al., 1990). 100 
Cells were pretreated with Co ions before exposure to the CoCr wear debris in order to detect 101 
any interactions between the ions and particle effects.  102 
 103 
Methods  104 
Preparation of wear debris 105 
Co-Cr wear debris was donated by DePuy International (Leeds, UK). A high-carbon cast 106 
0.2%)  cobalt chrome (ISO 5832-12: Co Balance, Cr 26.0±30.0%, Mo 5.0±7.0%, Ni 1.0% 107 
max., Si 1.0% max., Mn 1.0% max., Fe 0.75% max., C 0.35% max., N 0.25% max. 108 
(Dearnley, 1999) hip resurfacing implant was worn on a multi-station hip joint simulator 109 
using a non-standard protocol (personal communication, Dr C. Hardaker, DePuy 110 
International, Leeds, UK). The wear debris was produced over 250000 cycles using distilled 111 
water as the lubricating fluid. Wear debris produced by hip simulator under different 112 
conditions has previously been shown to be of similar size and  morphology to wear debris 113 
produced in vivo (Brown et al., 2007), Once produced, the wear debris was centrifuged at 114 
3500g for 20 minutes. The debris was heat-treated (180°C for 5h, 60kPa) in a vacuum oven 115 
to destroy any endotoxin. The dry debris was then suspended in sterile phosphate buffered 116 
saline (PBS; Invitrogen; Paisley, UK). Heat-treated wear debris was characterised with a 117 
Field Emission Scanning Electron Microscope (FE-SEM) (Hitachi SU-6600, Hitachi; 118 
Germany) at magnifications of 100-1000x. The sample was then transferred to a Scanning 119 
Electron Microscope (SEM) (Hitachi TM-1000, Hitachi; Germany). Energy Dispersive X-ray 120 
Spectroscopy (EDS) was used for quantitative analysis of elemental composition. Hitachi 121 
TM-1000 and EDSwift-TM software was used to obtain the images and chemical spectra of 122 
the wear debris. The sterility of the treated wear debris was tested as described elsewhere 123 
(Akbar et al., 2012)  by exposing dendritic cells (isolated from bone marrow of male BALB/c 124 
(Harlan, UK) mouse femurs and tibias (Lutz et al., 1999) to the debris for 24h, in vitro, and 125 
then assessing the expression of surface activation markers by flow cytometry. The debris 126 
was found not to increase the surface expression of CD40, CD86, or MHC II on these cells, 127 
and, therefore, the suspended debris was deemed sterile and endotoxin-free (data not shown).   128 
 129 
ICP-MS analysis of metal ion release from CoCr nanoparticles 130 
Experiments were carried out to determine the extent of metal ion release when wear debris 131 
was incubated with cultured cells in vitro. In order to assess the effects of foetal calf serum 132 
(FCS) and pH on the metal ion release, 2.5mg metal wear debris /1x106cells were incubated 133 
for 24h in RPMI-1640 medium in the presence and absence of FCS and complete RPMI-1640 134 
medium, pH 4. Controls of each condition with no metal debris were also present. Standards 135 
were prepared by diluting Multielement Standard Solution 1 for ICP (Sigma-Aldrich (Fluka); 136 
Dorset, UK) in RPMI-1640. Samples were analysed using an Agilent 7700x octopole 137 
collision system ICP-MS (Agilent Technologies; Wokingham, UK) in helium gas mode using 138 
scandium as internal standard.  139 
 140 
Human lymphocyte isolation 141 
Human buffy coat samples were collected from the Scottish Blood Transfusion Service 142 
(SNBTS), Glasgow, UK) with ethical permission from the SNBTS Committee for the 143 
Governance of Blood and Tissue Samples for Non-Therapeutic Use. All samples had been 144 
donated by anonymous healthy donors no more than 5h before use. Peripheral blood 145 
mononuclear cells (PBMCs) were isolated under sterile conditions from 60 ml of Buffy Coat 146 
by density gradient centrifugation using Histopaque-1077 (Sigma-Aldrich, Cambridge, UK), 147 
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and lymphocyte enrichment  performed as previously described (Martin-Romero et al., 148 
2000). Briefly, PBMC (2.5×106cells/ml) were incubated in a 75cm2 culture flask (TPP, 149 
Trasadingen, Switzerland) with complete RPMI-1640 for 1h at 37°C in a 5% (v/v) CO2 150 
chamber. The medium with the non-adherent cell suspension was then transferred to another 151 
culture flask and incubated for an additional 1h to further deplete the numbers of any 152 
monocytes present in the population. /\PSKRF\WH YLDELOLW\  DQG D PHDQ O\PShocyte 153 
yield of 5.89x106cells/ml (±0.61 SEM, n=3) was obtained. 154 
 155 
Exposure of lymphocytes to wear debris and metal ions  156 
Isolated peripheral human lymphocytes were exposed to metal wear debris and Co2+ in a 157 
resting state. Lymphocytes were cultured (1x105cells/well) in 96-well round-bottom plates 158 
ȝOZHOO ZLWK PJ ZHDU GHEULV[6FHOOV ȝ0 RI &R2+ and 5mg wear 159 
debris/1x106FHOOV FRPELQHG ZLWK ȝ0 RI &R2+ in complete RPMI-1640. Cultures were 160 
carried out for 24, 48, and 120h at 37°C under 5% (v/v) CO2 air. For apoptosis analyses, 161 
debris concentration was 2.5mg wear debris/1x106 cells, a lower concentration than for 162 
cytotoxicity studies, in order to facilitate detection of early apoptosis.  163 
 164 
Measurement of viability, proliferation and apoptosis 165 
At 24 and 120h, cell viability was assessed by the neutral red (NR) and MTT assays as 166 
described previously (Akbar et al, 2011). Proliferation was determined after 48 and 120h of 167 
exposure to the treatments using a BrdU Cell Proliferation Immunoassay kit (kit number 168 
QIA58, Merck Chemicals; Nottingham, UK), as suggested by the manufacturer. The 169 
absorbance  was measured using a Thermo Scientific Multiskan Ascent spectrophotometer 170 
plate reader (Thermo Scientific; Hampshire, UK) at dual wavelengths of 450±540nm. At 24 171 
and 48h post treatment, lymphocytes cells were collected by centrifugation and incubated for 172 
15min with phycoerythrin-labelled annexin V and 7-aminoactinomycin D in the dark. The 173 
samples were analysed by a FACSCanto flow cytometer (BD Bioscience, Oxford, UK), and 174 
all data were analysed using FACSDiva software. 175 
 176 
Cytokine secretion measured by ELISA 177 
Cytokine levels were determined by collecting the supernatants from cell cultures at 24 and 178 
120h following exposure to the treatments. The concentrations of tumor necrosis factor-alpha 179 
(TNF-Į LQWHUIHURQ-Ȗ ,)1Ȗ LQWHUOHXNLQ-2 (IL-2), and interleukin-6 (IL-6) in the culture 180 
media were determined from aliquots of cell-free isolates using Ready-Set-Go! ELISA kits 181 
H%LRVFLHQFH+DWILHOG8.LQDFFRUGDQFHZLWKWKHPDQXIDFWXUHU¶VLQVWUXFWLRQV(DFKRIWKH182 
kits had a sensitivity level of 4pg/ml, and linear standard curves were generated between 0-183 
SJPOIRU71)ĮDQG,)1Ȗ-250pg/ml for IL-2, and 0-200pg/ml for IL-6. The presence 184 
of high concentrations of metal ions did not interfere with detection of cytokines. 185 
 186 
Statistics 187 
Statistical analyses were carried out by a one-way analysis of variance (ANOVA), followed 188 
E\ D 'XQQHWW¶V PXOWLSOH FRmparison test. Significance was assigned where p values were 189 
found to be < 0.05. 190 
 191 
Results  192 
The aim of this study was to assess the toxicity of CoCr nanoparticles released from a 193 
resurfacing hip implant and Co ions on primary human lymphocytes. In order to achieve this, 194 
viability, proliferation, cytokine production, and apoptosis were evaluated in lymphocytes 195 
exposed to the ions and the CoCr wear debris particles.  196 
 197 
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Characterisation of heat treated wear debris 198 
SEM images show irregular shapes and sizes varying from the nano to the micro scale (from 199 
150nm to 6.5µm). The larger irregular shaped particles suggest that the debris aggregates 200 
(Image 1), and this has been reported previously by Akbar and coworkers (2012). Doorn et 201 
al(1998) isolated particles from MoM retrieval tissues that varied in size (51-116nm particles 202 
to micrometre sized aggregates) and shape. Moreover, metal particles (0.1-3 microns in size) 203 
have also been found in tissues post-mortem (Brown et al., 2013). EDS analysis indicated 204 
that the wear debris is primarily composed of Co and Cr, which is in agreement with the alloy 205 
composition (Singh and Dahotre, 2007). Analysis of 25 different particles indicated a mean 206 
composition of 59.57% (±1.15%) Co and 40.43% (±1.25%) Cr, with a small content of Mo 207 
which was below the quantification limit.   208 
 209 
Metal ion release into cell culture medium 210 
Metal debris was incubated, in the absence of cells, under different conditions. Analysis of 211 
ICP-MS results found that CoCr wear debris releases metal ions into culture medium (Figure 212 
1) was no significant difference (p>0.05) in ion release from metal debris in the presence and 213 
absence of 10% (v/v) FCS. This concentration of FCS was used as it was the concentration 214 
used when the Co-Cr wear debris was incubated with cells for up to 120h. In contrast to these 215 
data, the acidic pH 4.0 had a considerable effect as seen in the significant increase (p<0.05) in 216 
the levels of ion release compared with release in medium at normal physiological pH of 7.4. 217 
Even though Co was the ion predominantly released in all cases, the change in pH seemed to 218 
have a more pronounced effect on Cr ion release. 219 
 220 
Effects of metal debris and ions on human primary lymphocyte cell viability, proliferation 221 
and apoptosis.  222 
The viability of primary human lymphocytes was tested after 24 and 120h of exposure to 223 
5mg wear debris/1x106cells; ȝ0RI&R2+; and 5mg wear debris/1x106cells combined with 224 
ȝ0RI&R2+. In this study, the 5mg/1x106cells debris concentration was chosen to mimic 225 
the local metallosis environment surrounding an implant. There was a significant increase in 226 
cell number as indicated by the NR assay, measured both at 24 and 120h in the presence of 227 
metal debris when compared to controls (Figure 2). Although there was an initial increase in 228 
cell number (24h), there was no significant difference in the reduction of MTT in cells in the 229 
presence of metal wear debris. Co ions on their own did not seem to have an effect on cell 230 
number or cell metabolic activity. These findings suggest that the effects of the debris on the 231 
lymphocytes are due to the synergistic action of the nanoparticles and the Co and Cr ions 232 
released from the particles. 233 
 234 
Effects on cell proliferation were assessed with the BrdU cell proliferation assay after 48 and 235 
120h of treatment with 5mg wear debris/1x106cells; ȝ0 RI &R2+; and 5mg wear 236 
debris/1x106FHOOVFRPELQHGZLWKȝ0RI&R2+. At 48h, there is an initial decrease in cell 237 
proliferation followed by an increase by 120h of treatment (Figure 3). These results suggest 238 
an activation response of the cells to both debris and ions, where the cells overcome the 239 
initial growth arrest effect.   240 
 241 
To determine the effects of metal ions on cell damage leading to apoptosis, flow cytometry 242 
following Annexin V and 7-AAD staining at 24 and 48h of exposure was performed. To 243 
avoid cytotoxic effects and the growth arrest effect observed after exposure to 5mg, a lower 244 
debris concentration (2.5mg metal debris/1x106 cells) was used for apoptosis analysis in 245 
order to facilitate the detection of the process at early stages (to measure both early apoptosis 246 
and detect any repair). Apoptosis was not observed within 24h of exposure, but was evident 247 
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after 48h (Figure 5) where the debris caused apoptosis whereas the Co ions did not, and the 248 
effect of the debris was unaltered by preincubation with Co ions. 249 
 250 
Effects of metal debris and ions on cytokine release by human primary lymphocyte cells  251 
Interleukins such as IL-2, IL- ,)1Ȗ DQG 71)Į DUH UHJDUGHG DV LQGLFDWRUV RI WKH252 
inflammation evoked by particulate metals (Cachinho et al., 2013). Levels of these four 253 
cytokines were determined in the supernatants of human primary lymphocyte cultures after 254 
24 and 120h of treatment with cobalt ions and wear debris. There was a general decrease in 255 
cytokine production particularly when cells were in contact with metal particles (Figure 4). 256 
,)1Ȗ DQG ,/-6 levels decreased after 24h of exposure and continued to be low for 120h. 257 
71)ĮOHYHOVZHUHPDLQO\GHcreased after 120h of exposure. Interestingly, IL-2 was the only 258 
cytokine to be affected by all treatments.  Cobalt ion treatment did not have an effect on IL-6, 259 
,)1ȖDQG71)ĮSURGXFWLRQ 260 
  261 
 262 
Discussion 263 
Several studies have described accumulation of perivascular lymphocytes in tissue 264 
membranes around failed MoM implants apparently not associated with infection, and these 265 
authors have interpreted this inflammation as an immunologic reaction against metal ions or 266 
metal particles associated with those articulations (Bohler et al., 2002; Davies et al., 2005; 267 
Willert et al., 2005; Korovessis et al., 2006; Campbell et al., 2010). In the present study, 268 
primary human lymphocytes were exposed to Co ions and high concentrations of metal wear 269 
debris derived from a MoM hip resurfacing device in order to evaluate the cell response to 270 
these treatments and to assess whether or not CoCr particles and ions could activate primary 271 
cultures of human lymphocytes.  272 
 273 
The wear debris used in this study was produced from a 39mm ASRTM prosthesis, and 274 
previous work replicating natural gait on a simulator has shown that approximately 8 mm3 of 275 
debris is produced per million cycles from this prosthesis (Leslie et al., 2008). The density of 276 
the CoCr alloy used was 8.32mg/mm3 (Medley et al., 1996), so 66.56mg debris would be 277 
produced per million cycles. An active person might walk 3.5 million cycles per year, so 278 
232.96mg debris/year would be produced locally in the environment of the prosthesis. The 279 
5mg/1x106cells metal debris concentration used in this investigation was chosen to mimic 280 
metallosis, a situation where metallic debris infiltrates into the periprosthetic tissues, with 281 
resulting severe adverse effects. The range of debris and ion concentrations measured locally 282 
varies hugely in the literature, for example, in catastrophic failure of a prosthesis amounts of 283 
wear debris up to 67mg have been reported (Matziolis et al., 2003).  284 
 285 
Cellular uptake of the wear debris by the lymphocytes was not demonstrated in the present 286 
study primarily due to technical difficulties in proving uptake by SEM.  Showing specific 287 
uptake of the CoCr debris would have made a significant contribution to the study. However, 288 
uptake of dextran coated glass beads of similar size range was measured by fluorescent 289 
labelling proving that the lymphocytes were capable of phagocytosis.    290 
 291 
T-lymphocytes are normally maintained in a quiescent state while remaining capable of rapid 292 
responses and effector function (Macintyre and Rathmell). T-cell proliferation occurs as the 293 
result of a precisely orchestrated set of events involving two distinct signals, namely 294 
recognition of an antigen followed by release of co-stimulatory molecules such as IL-2 295 
cytokine (Deweck et al., 1984; Habetswallner et al., 1988). After activation, T cells undergo 296 
a transient period with little cell growth and then begin to rapidly grow and divide (Macintyre 297 
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and Rathmell). In this investigation, high concentrations of metal debris caused an increase in 298 
cell number despite the initial decrease in cell proliferation suggesting that the particles may 299 
exert a cell activation effect.  It is proposed that this took place during the first 48h of 300 
treatment reflected by the initial lower proliferation rates (24-48h) followed by the rapid 301 
growth and division seen by 120h. In addition to this, a significant decrease in IL-2 302 
production was observed after 24h of exposure to all the treatments. Since IL-2 is an 303 
important molecule for lymphocyte activation and proliferation, its diminished production 304 
could have contributed to the decrease in proliferation observed at 48h.  305 
 306 
A state of reduced function in which a viable, antigen-specific T cell is unable to respond to 307 
an immunogenic stimulus has been referred to as anergy (Zheng et al., 2008). Anergy can be 308 
induced under a number of circumstances that can be categorised as resulting from either a 309 
normal antigenic stimulus received in the absence of co-stimulation or from an altered and/or 310 
chronic T-cell receptor stimulus (Wells, 2009). To the authors¶ knowledge, anergy has not 311 
been described as part of the biological reaction to metal debris and ions, and most studies 312 
report implant-related hypersensitivity reactions, in particular type-IV delayed-type 313 
hypersensitivity mediated by T lymphocytes. Nevertheless, results from this investigation 314 
suggest that there may be an anergy-like response to high concentrations of metal debris. The 315 
significant decrease in IL-2 production and proliferation observed here are hallmarks of T-316 
cell anergy (Chappert and Schwartz, 2010; Kuklina, 2013). Moreover, defective production 317 
RILQIODPPDWRU\F\WRNLQHVVXFKDV,)1ȖDQG71)ĮLVDOVRDFKDUDFWHULVWLFRIDQHUJ\(Wells, 318 
2009) and significant decreases in both cytokines were observed in the present study in the 319 
presence of metal debris.  320 
 321 
Metals corrode in vivo releasing metal ions (Hanawa, 2004). Such ions can potentially bind to 322 
proteins, remain in solution, or disseminate into the surrounding tissues and bloodstream, and 323 
thus reach remote organs.  The microenvironment conditions surrounding the debris can 324 
influence the rate of ion release (Cadosch et al., 2009).  It is generally presumed that metal 325 
ions facilitate cell activation and sensitization. However, depending on the concentration of 326 
metal ions present, they may also be cytotoxic and suppressive. It has been shown that 327 
SURGXFWLRQRI71)ĮDQG,/-6 by human peripheral blood mononuclear cells exposed to Cr (1, 328 
5, and 10µM) significantly decreases (Villanueva et al., 2000). In the current investigation, 329 
LQKLELWLRQ RI F\WRNLQH SURGXFWLRQ ZDV REVHUYHG LQ WKH SUHVHQFH RI PHWDO SDUWLFOHV ,)1Ȗ330 
71)ĮDQG,/-6 levels did not seem to be affected by Co ions alone, whereas IL-2 levels were 331 
decreased. Although the effects of Cr may be related to the regulation of 71)ĮDQG,/-6, IL-332 
2 production is more likely to be modulated by Co. Additionally, high concentrations (5mg 333 
debris/1x106cells) of metal debris were not cytotoxic to primary lymphocytes. However, a 334 
marked increase in apoptosis was observed at a lower dose (2.5mg debris/1x106cells). These 335 
findings suggest a dose dependent effect on cell damage pathways.  Akbar et al. (2011) 336 
exposed resting and activated lymphocytes to a range of Co and Cr ions. They found that 337 
exposure to higher concentrations of Cr6+ DQGȝ0DQG&R2+ ȝ0VLJQLILFDQWO\338 
decreased cell viability and increased apoptosis in both resting and activated lymphocytes at 339 
24 and 48h of exposure. In their study metal ions were assessed independently. The effects 340 
observed in the current study are the results of the concerted action of the particles and both 341 
Co and Cr ions. It would have been interesting to pre-incubate the cells with Co ions and 342 
subsequently treat them with the particles to identify if sensitisation occurs. In fact, priming 343 
human monocyte-like U937 cells with Co ions for subsequent challenge with wear debris has 344 
been investigated in our laboratory (Posada et al., 2014). Results from such investigation 345 
showed that metal debris was more effective as an inducer of apoptosis and gene expression 346 
when cells had been pre-treated with Co ions. However, this set of experiments could not 347 
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readily be performed with the primary lymphocytes due to difficulties in maintaining 348 
prolonged culture. 349 
 350 
Released metal ions can activate the immune system by forming metal-protein complexes 351 
that are considered to be candidate antigens for eliciting hypersensitivity responses 352 
(Korovessis et al., 2006). Upon recognition by lymphocytes, the metal-protein complexes 353 
induce the production of proinflammatory cytokines and chemokines by various cell types 354 
due to triggering of innate immune responses (Martin, 2004). According to this, it is thought 355 
that high local metal ion and nanoparticles concentrations facilitate a T-lymphocyte mediated 356 
inflammatory response resulting in the destruction seen around the prostheses (Davies et al., 357 
2005; Willert et al., 2005; Boardman et al., 2006; Kwon et al., 2010). Three mechanisms 358 
have been proposed by which metal±protein complexes can activate lymphocytes: 1. antigen-359 
independent, 2. antigen-dependent, and 3. superantigen-like, which is a synergistic 360 
combination of the first two mechanisms (Hallab et al., 2001b). Metals may act with serum 361 
proteins to crosslink lymphocyte receptors (e.g., BV17 of CDR1 T cell receptor) without the 362 
presence of an antigen-presenting cell leading to a superantigen enhancement of T cell 363 
receptor-protein contact (Vollmer et al., 1997; Vollmer et al., 1999). In this circumstance, 364 
proteins or peptides that would not otherwise be antigenic are able to provoke a response 365 
(Hallab et al., 2001b). The lymphocyte reactions in the current investigation seem to be 366 
consistent with such nonspecific mitogenic activation mechanisms, which could explain the 367 
increase in cell proliferation despite the significant decrease in IL-2 production. 368 
 369 
Implant failure is largely caused by aseptic loosening and osteolysis (Huber et al., 2010) in 370 
response to accumulation of metal particles in the periprosthetic tissues, which also generates 371 
inflammation, pain, and pseudotumours (Langton et al., 2011). Evidence of systemic effects 372 
can also be found in multiple reports (Steens et al., 2006; Oldenburg et al., 2009; Rizzetti et 373 
al., 2009; Ikeda et al., 2010; Tower, 2010; Machado et al., 2012; Pelclova et al., 2012; 374 
Tower, 2012) describing patients with MoM implants who presented symptoms including 375 
neurological symptoms such as auditory impairment/deafness, visual impairment/blindness, 376 
peripheral neuropathy/dysesthesia of the extremities, poor concentration/cognitive decline, 377 
cardiomyopathy and hypothyroidism. All patients had elevated cobalt and/or chromium 378 
concentrations in their blood, serum, plasma, and/or urine, suggesting that these systemic 379 
symptoms may be due to metal toxicity as a result of excessive implant wear. Polyzois et al 380 
(2012), reviewed the evidence of local and systemic toxicity of wear debris from total hip 381 
arthroplasty. They found extensive evidence and experimental data supporting the fact that 382 
orthopaedic metals induce local immunological effects characterised by an unusual 383 
lymphocytic infiltration and cell-mediated hypersensitivity. In terms of systemic toxicity, 384 
there are in vivo and in vitro experimental, as well as a limited number of epidemiological 385 
studies, where the systems most commonly involved are haematopeietic, immune, 386 
hepatobiliary, renal, respiratory, nervous, cardiovascular, musculoskeletal, skin, and 387 
endocrine and reproductive.  Concern has been raised regarding a potential link between 388 
metal wear debris and carcinogenesis.  In an attempt to address this, Christian et al (2014) 389 
used quantitative methods to evaluate the relationship between CoCr-containing hip implants 390 
and increased cancer risk. They concluded that although the evidence suggests that such 391 
implants are unlikely to be associated with an increased risk of systemic cancers, additional 392 
research is warranted in this area. 393 
 394 
The importance of Co ions in the inflammatory responses to CoCr particles has been 395 
recognised, and chronic exposure to circulating levels of ions, plus high local concentrations 396 
may act synergistically in vivo to trigger and promote implant loosening (Hallab et al., 2001a; 397 
9 
 
Caicedo et al., 2010; Hart et al., 2012). The present study has shown that high concentrations 398 
of wear debris, derived from a CoCr MoM hip resurfacing, induce lymphocyte proliferation 399 
and inhibit cytokine production after 120h exposure.  The fact that IL-2 production was 400 
affected by 0.1µM Co (5.9ppb or 5.9µg/L) suggests that even circulating blood metal ion 401 
concentrations within the MHRA guideline levels of 7ppb or 7µg/L (MHRA) may contribute 402 
to the impairment of immune regulation in patients with MoM implants. 403 
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Figure and Image legends  623 
 624 
Image 1. Scanning Electron Microscopy images of simulator generated wear debris 625 
from an ASR hip implant. Image taken at 5000X with a FE-SEM Hitachi SU-6600. 626 
 627 
Figure 1. Metal ions in RPMI-1640 in the presence and absence of metal wear debris. 628 
Results are expressed as mean values (±SEM, n=3). (a) Cr ion concentrations. (b) Co ion 629 
concentrations. *Significantly different from control values (p<0.05) by one-way ANOVA 630 
IROORZHGE\'XQQHWW¶VPXOWLSOHFRPSDULVRQWHVWbSignificant difference between pH 7.4 and 631 
pH 4.0.  632 
 633 
Figure 2. Cell number (NR) and metabolic activity (MTT) of human lymphocytes. 634 
Results are expressed as percentages (±SEM, n=12) where 100% represents control untreated 635 
cells. (a) Effects on cell number as measured by NR. (b) Cell metabolic activity as measured 636 
by MTT. *Significantly different from control values (p<0.05) by one-way ANOVA followed 637 
E\'XQQHWW¶VPXOWLSOHFRPSDULVRQWHVW 638 
 639 
Figure 3. Proliferation of human lymphocytes measured by BrdU assay. Results are 640 
expressed as percentages (±SEM, n=6) where 100% represents control untreated cells. 641 
*Significantly different from control values (p<0.05) by one-way ANOVA followed by 642 
'XQQHWW¶VPXOWLSOHFRPSDULVRQWHVW  
14 
 
 644 
Figure 4. Cytokine production by human lymphocytes. Results are expressed as mean 645 
values (±SEM, n=4). (a) TNF-Į OHYHOV E ,1)-Ȗ OHYHOV F ,/-6 levels. (d) IL-2 levels. 646 
*Significantly different from control values (p<0.05) by one-way ANOVA followed by 647 
'XQQHWW¶VPXOWLSOHFRPSDULVRQWHVW  648 
 649 
Figure 5. Early and late apoptosis. Results are expressed as percentages (±SEM, n=12). (a) 650 
Percentage of early apoptosis after 24h of treatment. (b) Percentage of late apoptosis after 651 
24h of treatment. (c) Percentage of early apoptosis after 48h of treatment. (d) Percentange of 652 
late apoptosis after 48h of treatment. *Significantly different from control values (p<0.05) by 653 
one-ZD\$129$IROORZHGE\'XQQHWW¶VPXOWLSOHFRPSDULVRQWHVW 654 
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